Needham maintains Pacira BioSciences [PCRX] at Buy rating with a $76 price target
Needham maintained its Pacira BioSciences [PCRX] rating to the equivalent of Buy but changed the price target to $76.0 from $67, in a research note dated 2021-01-08. That figure represents around a 12.31% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Needham’s analysts reiterating the shares to […]
